Historique du chiffre d'affaires, des bénéfices et des flux de trésorerie d'après les états financiers officiels.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
Voir les graphiques interactifs et les états complets → Modèle de valorisation (DCF) →
| Compte de résultat | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiffre d'affaires total | $2.1B | $2.1B | $2.0B | $2.0B | $2.1B | $2.3B | $1.9B | $1.5B | $1.5B | $1.4B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.2B | $1.1B | $1.0B | $893M | $650M | $466M |
| Bénéfice brut | $1.3B | $1.3B | $967M | $1.2B | $1.4B | $1.5B | $1.2B | $1.0B | $1.0B | $923M | $845M | $827M | $865M | $815M | $824M | $750M | $716M | $667M | $600M | $434M | $325M |
| Marge brute % | 61.8% | 61.8% | 48.9% | 62.8% | 64.6% | 64.4% | 65.9% | 65.9% | 66.6% | 65.1% | 63.1% | 64.5% | 64.3% | 62.6% | 65.7% | 64.1% | 65.8% | 66.1% | 67.2% | 66.7% | 69.7% |
| Résultat opérationnel (EBIT) | $541M | $520M | $98M | $410M | $531M | $630M | $386M | ($26M) | $267M | $153M | $99M | $179M | $162M | $63M | $170M | $100M | $189M | $180M | $146M | $83M | $101M |
| Marge opérationnelle % | 25.8% | 24.9% | 4.9% | 20.9% | 24.8% | 28.0% | 20.7% | -1.7% | 17.8% | 10.8% | 7.4% | 14.0% | 12.0% | 4.9% | 13.5% | 8.5% | 17.3% | 17.8% | 16.3% | 12.8% | 21.6% |
| Résultat net | $409M | $425M | $84M | $341M | $423M | $513M | $359M | ($41M) | $190M | $40M | $80M | $130M | $116M | $69M | $130M | $96M | $144M | $138M | $89M | $50M | $71M |
| Marge nette % | 19.5% | 20.3% | 4.2% | 17.4% | 19.8% | 22.8% | 19.2% | -2.7% | 12.7% | 2.9% | 6.0% | 10.2% | 8.6% | 5.3% | 10.3% | 8.2% | 13.3% | 13.6% | 10.0% | 7.7% | 15.1% |
| EBITDA | — | $717M | $368M | $689M | $779M | $895M | $716M | $228M | $499M | $381M | $309M | $365M | $360M | $268M | $366M | $289M | $344M | $322M | $263M | $195M | $140M |
| Bénéfice par action (EPS) | $1.95 | $2.04 | $0.38 | $1.57 | $1.90 | $2.28 | $1.58 | $-0.19 | $0.82 | $0.17 | $0.35 | $0.57 | $0.50 | $0.30 | $0.56 | $0.42 | $0.62 | $0.67 | $0.45 | $0.30 | $0.48 |
| Actions en circulation (M) | — | 208M | 218M | 217M | 223M | 225M | 227M | 220M | 233M | 233M | 230M | 228M | 233M | 233M | 232M | 230M | 232M | 206M | 197M | 169M | 148M |
Source : rapports publics de la société (SEC). Vérifiez sur SEC EDGAR avant de vous fier à tout chiffre.
Bilans, flux de trésorerie, données trimestrielles et ratios complets dans le visualiseur interactif de QGEN. /companies/us/QGEN
Les informations de ce site sont fournies à des fins éducatives et informatives uniquement ; elles ne constituent pas un conseil en investissement. Aucun objectif de cours ni recommandation n'est publié.
About TickerBase · Data methodology & sources · Privacy · Terms